Phase 2 Study of aTezolizumab, bevAcizumab, and Cobinetinib (TACo) in patients (pts) with PD1 refractory metastatic brain metastases (MBM)
Authors
Elizabeth Burton,
V. HonakerDenái Milton,
Isabella Glitza,
R. Amaria,
Sapna Patel,
Adi Diab,
Michael Wong,
J. McQuade,
Caroline Chung,
Jeffrey Wefel,
J. Li,
Michael Davies +11 authors
,
Hussein Tawbi Tip Tip